Ascendiant Capital Markets Issues Pessimistic Forecast for AIM ImmunoTech (NYSEAMERICAN:AIM) Stock Price

AIM ImmunoTech (NYSEAMERICAN:AIM) had its price objective cut by analysts at Ascendiant Capital Markets from $9.00 to $7.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

AIM ImmunoTech Stock Performance

Shares of AIM opened at $0.24 on Thursday. The firm has a market capitalization of $7.25 million, a price-to-earnings ratio of -0.08 and a beta of 1.20. AIM ImmunoTech has a one year low of $0.19 and a one year high of $2.98. The stock’s fifty day moving average is $0.29 and its 200-day moving average is $0.54.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.43) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter. Analysts forecast that AIM ImmunoTech will post -0.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in AIM ImmunoTech stock. DRW Securities LLC lifted its stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,545 shares of the company’s stock after acquiring an additional 26,254 shares during the quarter. DRW Securities LLC owned about 2.12% of AIM ImmunoTech worth $79,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.